to shell out Rs. 300 Cr. for Core Healthcare acquisition
FMCG major Nirma is expected to
shell out around Rs 300 Crore for the acquisition of Ahmedabad-based Core
Healthcare, the largest intravenous (IV) fluids manufacturer in the country.
Though a memorandum of understanding to acquire the pharma company was signed
three months ago, Nirma has since neither announced the payment details nor the
structure of the deal. Nirma has been eyeing the healthcare sector for a while
and this would give it a solid platform in the segment.
Insurance Market And Third Party Administrators (TPA)
If the business of insuring
people's health involves an element of gambling, what plagues this industry's
growth is the distrust between hospitals and the middlemen appointed by
insurance firms who scrutinize a doctor's decision for repayment. While chiefs
of leading hospitals believe the third party administrators (TPAs) appointed by
insurance firms to process claims, are too bureaucratic and often delay
payments, there is criticism about 'over caring' by doctors leading to inflated
Edu. And Medical Group (India) Signs MoU with German Company For Hospital Waste
Manipal Education and Medical
Group (MEMG) has signed a memorandum of understanding (MoU) with Deuttsche
Gesellschaft fur Technische Zusammenarbeit (GTZ), Germany, to set up a first of
its kind state-of-the-art 'centre of excellence in waste management' at Manipal
Hospital, Bangalore. The centre will develop intellectual properties in the
field of environment management, while Manipal Academy of Higher Education (MAHE)
will offer Diploma courses in the area of environmental and waste management.
Alzheimer urine test kit to hit European markets
Nymox Pharmaceutical Corporation
has entered into distribution agreements for the marketing and sale of its
AlzheimAlert test kit with medical diagnostic companies in Europe.
Health Signs MoU With SBI For Financing Apollo Clinics Franchises
Apollo Health & Lifestyle (AHLL),
a wholly-owned subsidiary of Apollo Hospitals, on Friday said it has signed an
MoU with State Bank of India to offer term loans to its franchises. Under the
MoU, AHLL will nominate State Bank of India as its preferred financier to its
prospective franchises for opening of Apollo clinics throughout India, AHLL said
in a release. The MoU was signed between Ratan Jalan, CEO AHLL and J
Chandrasekaran, General Manager, SME Business Unit, State Bank of India.
launches automatic insulin delivery devices
Pharmaceutical major Wockhardt
Ltd has launched India's first automatic insulin delivery device specially
designed for the convenience of Indian diabetic patients.
to consolidate Indian operations
Surgical Information Systems
(SIS) to consolidate its Indian operations based at Hyderabad and signs up with
new clients globally to be supported from its India development cum support
Concepts to launch combination drug eluting stent
Bangalore based Vascular
Concepts, a leading company engaged in the design, development and manufacture
of endovascular medical devices, plans to launch combination drug eluting stent
soon. Speaking to Express Pharma Pulse, Swaminathan M Jayaraman, chief executive
office, Vascular Concepts, said that the combination drug eluting stent shall
enable to target different cells at the same time.
to invest Rs 10 crore in Pune Facility
Fresenius Kabi India Pvt Ltd, a
wholly owned subsidiary of Fresenius Kabi AG, Germany, is planning to increase
its presence in the country in a big way. The company is in the process of
upgrading its manufacturing facility to meet European Union Good Manufacturing
Practice (regulatory standards) and expects a 20 per cent growth in its turnover
in the next year.
drug industry delegation visits Indian drug firms
An 11-member drug industry
mission from Mexico, facilitated by Confederation of Indian Industry (CII), is
exploring business opportunities in India. The delegation is having interactions
with leading domestic companies, research institutions and government
launches latest DES-COSTER for coronary heart disease
Technologies Pvt. Ltd.) has launched COSTAR, the latest generation drug eluting
stent (DES), to treat Coronary Heart Disease (CHD). COSTAR is a product of
ConorMed USA. The product makes use of "Reservoirs" or holes which are
made in the stent itself and which houses the drug and the polymer rather than
coating the stent surface with the polymer and the drug. This results in
overcoming the problems of polymer cracking when the stents have to be implanted
in more difficult and tortuous arteries.